CJC-1295 and Ipamorelin: With DAC or Without?

CJC-1295 ipamorelin with DAC or without comes down to one variable: half-life. CJC-1295 with DAC stays active for roughly six to eight days because it binds to albumin, while CJC-1295 without DAC clears in about 30 minutes and is usually stacked with ipamorelin to create a short, sharp growth hormone pulse. Neither peptide is FDA-approved for human use in the United States, and both are sold as research chemicals only.

The DAC Difference in Plain Terms

CJC-1295 with DAC carries a maleimidopropionic acid group that attaches the peptide to circulating albumin. That attachment is the whole trick — it shields the peptide from rapid breakdown and stretches its half-life from minutes to roughly a week.

CJC-1295 without DAC is the same GHRH backbone minus that binding group, and it is often labeled Mod GRF 1-29 or CJC-1295 (no DAC). Its half-life is close to 30 minutes, so it produces a brief burst of growth hormone release rather than a long, steady elevation.

Search results sometimes frame the topic as cjc-1295 with dac vs ipamorelin, but that comparison mixes two different mechanisms. CJC-1295 acts on GHRH receptors, while ipamorelin acts on the ghrelin receptor, so they are complements rather than competitors.

With DAC vs. Without DAC at a Glance

The table below summarizes the differences that matter most when these two versions are compared in research settings. All figures come from published research or public discussion, not from clinical guidance for human use.

Feature	CJC-1295 with DAC	CJC-1295 without DAC
Half-life	About 6–8 days	About 30 minutes
Albumin binding	Yes	No
Target receptor	GHRH receptor	GHRH receptor
GH release pattern	Sustained elevation	Short pulse
Typical research dose	1–2 mg once weekly	100–200 mcg per injection, 1–3 times daily
Ipamorelin pairing	Often added for pulse quality	Very commonly dosed together
Monitoring focus	IGF-1, glucose, pituitary response	IGF-1, injection timing

What the Published Data Suggests

A 2006 study in healthy adults found that a single CJC-1295 with DAC dose raised growth hormone and IGF-1 levels for up to six days. That long window is why weekly dosing appears in so many discussions.

Human data on CJC-1295 without DAC is much thinner, and most of what circulates online comes from rodent work and user reports. That gap matters when weighing the two options.

Why Ipamorelin Gets Added to the Mix

Ipamorelin is a selective ghrelin receptor agonist that triggers a growth hormone pulse with minimal effect on cortisol or prolactin in animal models. Because it hits a different receptor than CJC-1295, the two are often combined to widen the GH signal.

Suppliers frequently sell a 1:1 blend, and you will often see it listed as cjc-1295 without dac 5mg ipamorelin 5mg. That ratio simplifies measuring but says nothing about safety or legal status.

Dosing and Timing Patterns

How often do you inject cjc-1295 ipamorelin? Most protocols using the no-DAC version call for one to three injections per day, because each injection only produces a short pulse.

The best time to take cjc 1295 ipamorelin is usually in the evening or right before sleep, when natural growth hormone release peaks. Some protocols add a morning or post-workout dose, which is why the morning-or-night debate never really settles.

A commonly discussed cjc-1295 dac with ipamorelin dosage is one weekly CJC-1295 injection of about 1 to 2 mg combined with daily ipamorelin. No controlled human trial has validated that combination.

• With DAC: one injection per week, sometimes paired with daily ipamorelin.
• Without DAC: 100–200 mcg of each peptide, one to three times per day.
• Meal spacing: injections are usually kept 30–60 minutes away from food, since glucose and insulin blunt GH release.

Safety, Legality, and What to Watch

Neither CJC-1295 nor ipamorelin is FDA-approved for human use, and both appear on the FDA's category 2 bulk substances list, which restricts compounding pharmacies from using them.

Reported side effects in user accounts include injection site irritation, water retention, tingling in the hands, joint discomfort, fatigue, and changes in blood sugar. Long-acting GHRH analogs also raise a theoretical concern about pituitary desensitization, since the receptor is never allowed to return to baseline.

Anyone weighing personal use should talk with a healthcare professional, particularly anyone with diabetes, thyroid disease, or a history of hormone-sensitive cancer.

Which Version Fits a Research Question Better?

• Choose CJC-1295 without DAC when the goal is to study pulsatile GH release, because it mimics the body's natural rhythm.
• Choose CJC-1295 with DAC when the goal is to study sustained IGF-1 elevation with fewer injections.
• Add ipamorelin to either version when the research question involves two receptor pathways at once.

There is no single correct answer to the with-DAC-or-without question. The better choice depends on the GH pattern being studied, not on which version is more popular in online forums.

COMMON QUESTIONS

Frequently Asked Questions

Is CJC-1295 with DAC or without DAC better for stacking with ipamorelin?

It depends on the goal. CJC-1295 without DAC is the more common pairing with ipamorelin because both produce short pulses that can be timed together. CJC-1295 with DAC is chosen when sustained IGF-1 elevation is the research focus, and ipamorelin is sometimes added on top for pulse quality.

Are CJC-1295 and ipamorelin legal in the United States?

Neither peptide is FDA-approved for human use in the United States. Both appear on the FDA's category 2 bulk substances list, which blocks compounding pharmacies from using them, so they are legally sold only as research chemicals for laboratory use.

What side effects are reported with CJC-1295 and ipamorelin?

Commonly reported effects include injection site irritation, water retention, numbness or tingling in the hands, joint discomfort, fatigue, and blood sugar changes. Long-acting CJC-1295 with DAC also raises a theoretical concern about pituitary desensitization with continuous use, and no long-term human safety data exists for either peptide.